Skip to content

Rampart Duo Clinical (RaDical) Post-Market Study

Rampart Duo Clinical (RaDical) Study: An Exempt Minimal Risk Post-Market Evaluation of Clinical Outcomes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03974711
Acronym
RaDical
Enrollment
197
Registered
2019-06-05
Start date
2017-10-02
Completion date
2022-10-03
Last updated
2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Degenerative Disc Disease

Brief summary

This exempt, minimal risk, prospective, post-market, registry, multi-center, Institution Review Board (IRB) approved observational clinical evaluation was conducted at 10 centers. A total of 197 patients were enrolled. The evaluation collected data in a real-world patient population and was a data collection initiative only. No patient treatments or care were performed as a component of the protocol. All patient care received was on-label and standard of care for lateral lumbar interbody fusions. The data collected in this evaluation is intended to contribute to the body of literature for lateral lumbar interbody fusions.

Detailed description

The purpose of this study was to collect data that reports on the clinical outcomes of patients that were treated with the Spineology Rampart DUO device in a standard of care instrumented lateral lumbar interbody fusion procedure at one or two contiguous levels from L2-L5. Data was collected prospectively at specified time points per protocol and included both objective and subjective measures. The study concluded when the final patient achieved their 12-month evaluation.

Interventions

OTHERIn this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort.

There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.

Sponsors

Spineology, Inc
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* A clinical decision has been made to treat the patient with the Rampart Duo Interbody Spacer prior to enrollment into this research evaluation. This decision is independent (made outside) of the decision to take part in the research.

Exclusion criteria

* Previous interbody fusion or total disc replacement at the index level(s). * Enrolled in a concurrent clinical investigation that may confound the findings of the present investigation.

Design outcomes

Primary

MeasureTime frameDescription
Long-term objective 1: Patient Low back function change over timeThrough 12 months postoperative.Low back function determined on Oswestry Disability Index (ODI) and compared to baseline.
Short-term objective 1: New onset of thigh symptoms -- Anterior Thigh Pain Change from Baseline3 monthsChange from Baseline anterior thigh pain score through 3-months. Pain assessment captured on 100 mm VAS. A higher VAS score represents a worsening of pain.
Short-term objective 1: New onset of thigh symptoms -- Thigh Neurological Change from Baseline3 monthsChange from baseline in anterior thigh neurological assessment through 3 months. Anterior Thigh Neurological deficit defined as a negative change in strength (hip/flexor weakness) or sensation (anterior thigh).
Short-term objective 2: Hospital economics -- Blood LossEBL collected at time of surgery.Estimated blood loss (EBL) shall be compared to published literature.
Short-term objective 2: Hospital economics -- Duration of SurgeryDoS collected at time of surgery.Duration of surgery (DoS) defined as time from incision to closure shall be compared to published literature.
Short-term objective 2: Hospital economics -- Time-to-DischargePerioperative.Time-to-discharge (TTD) defined as time from hospital admission to the time the subject is discharged from the hospital and it shall be compared to published literature.
Long-term objective 1: Patient Low back pain change over timeThrough 12 months postoperative.Pain measured on 100 mm VAS and compared to baseline.

Secondary

MeasureTime frameDescription
Additional Outcomes 1 - Radiographic AssessmentsAssessed at 12 months postoperative.Assess for fusion status

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026